MedTrace Logo

ImmunoPET With an Anti-CD8 Imaging Agent

NCT04029181 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2024-05-03

No results posted yet for this study

Summary

This is a single-center, single-arm, investigator sponsored trial designed to evaluate the PK of the anti-CD8 imaging agent in patients prior to and during treatment with checkpoint inhibitors.

Conditions

Interventions

OTHER

Anti-CD8 PET imaging agent

An imaging agent radiolabelled with 89Zr developed for in human PET imaging of CD8

Sponsors & Collaborators

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • E. G.E. de Vries, MD, PhD · University Medical Center Groningen

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-14
Primary Completion
2022-12-28
Completion
2024-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04029181 on ClinicalTrials.gov